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A commentary on
Circulating type-1 anti-tumor CD4+ T
cells are preferentially pro-apoptotic in
cancer patients
by Wesa AK, Mandic M, Taylor JL, Moschos
S, Kirkwood JM, Kwok WW, Finke JH,
Storkus WJ. Front Oncol (2014). 4:266. doi:
10.3389/ fonc.2014.00266
We have read with great interest the
article by Wesa and colleagues in Fron-
tiers in Oncology (1) describing the anti-
tumor immune dysfunction in patients
with melanoma and renal cell carcinoma.
Accumulating evidence suggests that, in
patients with cancer, the state of sys-
temic immunity is not “normal”; rather,
it is repolarized toward a state of Th-
2 biased “chronic inflammation,” leading
to suppression of cytotoxic CD8 T-cell
function (2, 3). In this publication, the
authors show that, in addition to this func-
tional deficiency, tumor-associated antigen
(TAA)-specific (but not total or viral spe-
cific) CD4+ T-cells are prone to express
a pro-apoptotic phenotype in patients
with active cancer. Similarly to previous
reports, they show that there is evidence
of immune activation in the peripheral
blood of patients with advanced malignan-
cies, manifested by increased frequencies
of tumor-specific CD4+ T-cells in patients
with active disease as opposed to patients
rendered no evidence of disease (NED);
however, these cells seems to have an
enhanced sensitivity to activation-induced
cell death (AICD) via an apoptotic mecha-
nism. Interestingly, they found that female
patients with melanoma had significantly
higher frequencies of TAA-specific T-cells
as compared to male patients, raising the
possibility of sex differences in anti-tumor
immunity in this disease. This is very
intriguing as malignant melanoma has not
classically been viewed as a hormone-
sensitive neoplasm; however, an accumu-
lating body of evidence suggests that the
outcome of established melanoma is influ-
enced by endocrine status (4–6). Epidemi-
ological studies have consistently shown
that males have poorer survival rates
when compared to females. Specifically,
men seem to present with prognostically
worse primary tumors (thicker primary
melanomas with a higher incidence of
ulceration), that they have a higher prob-
ability of developing metastases, and that
they experience a shorter survival com-
pared with women (4, 5). Possible rea-
sons for these differences were thought to
be due to differences in detection (7, 8),
given that males are reportedly less likely
to self-detect their melanomas (7), make
fewer visits to health-care providers, and
are less likely to engage in preventive behav-
iors (8). However, gender seems to remain
an independent prognostic indicator even
after adjustment for these factors; addi-
tionally, when disease progression takes
place, women seem to progress more fre-
quently to local sites in the form of satel-
lite or in-transit metastases, while men
exhibit more frequently direct regional
lymph node metastases or show further
progression to distant sites (4). It has
therefore been suggested that these dif-
ferences may be due to estrogen status,
as data suggest that the female survival
advantage may not persist after menopause
(5, 6). We have recently analyzed data
from the National Cancer Institute sur-
veillance, epidemiology, and end results
(SEER) program, including 87,165 cases
of primary invasive melanoma diagnosed
between 1992 and 2009 and similarly found
that melanoma-specific survival was signif-
icantly poorer for males as compared to
females for localized and regional disease
for all age groups, suggesting that sex may
influence local and regional cancer pro-
gression (9). Therefore, we postulate that a
biological basis may be responsible for the
consistently observed differences in clini-
cal outcomes in patients with malignant
melanoma, such as the existence of sex
differences in immunity.
The sexual dimorphism in the immune
system of female and male patients has
long been recognized by the existence
of sex differences in the incidence and
course of autoimmune diseases (10, 11).
It has been recently postulated that these
immune differences could also be of rel-
evance to the natural course and surviv-
ing chronic inflammatory conditions such
as cancer. Nevertheless, the molecular dif-
ferences for the sex-based differences in
the outcome of malignant melanoma and
other malignancies remain undefined, and,
as of yet, the mechanism of this appar-
ent female survival benefit has neither
been investigated in any great depth nor
have its implications been exploited with
respect to therapy. In their article, Wesa
et al. (1) speculate that the increased num-
ber and/or improved function of tumor-
specific T-helper (Th) cells could serve
as a foundation for exploring and under-
standing these clinical observations. Th1
cells can mediate the anti-tumor effects
through a variety of mechanisms (12) and
are therefore important therapeutic tar-
gets. In recent years, the Programed cell
death 1 (PD-1) pathway has been found to
play an important role in tumor-induced
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immune suppression (13) in melanoma
and is an increasingly exploited thera-
peutic target in this disease and other
advanced malignancies (14–16). While a
role for sex-hormone modulation of PD-
1 has emerged, the published literature is
limited to animal studies and offers con-
flicting findings. For instance, preclinical
studies suggest that the expression and
function of PD-1 are responsive to sex
steroids, and that the hormone-mediated
effects on PD-1 signaling pathway play
important roles in mediating autoimmu-
nity (17–19). The expression of the PD-
1 ligand, PD-L1, or B7-homolog 1 (B7-
H1) has also been shown to be modu-
lated in an estrogen-dependent and sex-
dependent manner (20). One recent study
examined B7-H1 expression on regulatory
T-cells (Treg) in B-16 melanoma bearing
mice. Interestingly, despite comparable B7-
H1 expression, female mice were more
sensitive to PD-L1 blockade, and treat-
ment with an anti-B7-H1 blocking mon-
oclonal antibody reduced tumor growth to
a greater degree in females compared to
male mice, as a result of greater reduc-
tion in Treg function and increase in
tumor-specific cytotoxic (CD8) T-cells in
females (20). The reasons for this differ-
ential PD-1/B7-H1 signaling in male ver-
sus female mice are not known. Notably,
there are few studies published regard-
ing sex-hormone modulation of PD-1/B7-
H1 pathway in cancer, and work of this
nature in humans is non-existent, despite
accumulating evidence that this pathway
plays a pivotal role in tumor-induced
immune suppression (21). We believe that
identification of sex-dependent differences
in immune regulatory pathways impor-
tant for immune evasion in melanoma
and other advanced cancers will address
an important question – whether males
and females respond differently to certain
immune therapies – a fact not incorporated
into most clinical trial designs. Despite
early successes with novel immune agents,
preclinical models indicate that combina-
torial therapies are likely to deliver maxi-
mum clinical impact; therefore, elucidation
of the mechanisms responsible for these
sex-based immune differences may identify
novel treatment strategies for improving
the protective aspects of T-cell immunity in
malignant melanoma and other advanced
malignancies.
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